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Abstract
Background. Growing evidence suggests that activation of blood coagulation exerts protective functions 
during inflammation. However, it has been hypothesized that dysregulated immunothrombosis may lead 
to venous thromboembolism (VTE). Antinuclear antibodies (ANAs) are considered to promote the thrombotic 
tendency but there have been no reports on the association between ANAs and VTE.
Objectives. The objective of this study was to investigate if the presence of ANAs is associated with VTE.
Material and methods. We enrolled 283 consecutive patients, aged 18–66 years old, following a VTE 
episode, and 165 age-matched healthy controls. Patients with documented autoimmune diseases (n = 56, 
19.79%), including antiphospholipid syndrome (n = 48, 16.9%), were excluded. Antinuclear antibodies were 
determined based on immunofluorescence. The specific immunofluorescence patterns observed at serum 
dilution equal to or greater than 1:100 were considered as positive ANAs.
Results. The final analysis included 227 patients (aged 41.07 ±11.4, 98 males, 129 females) following 
provoked (n = 111) or unprovoked (n = 116) VTE. Ninety-four (42.2%) patients had positive ANAs, including 
32 (33.3%) with ANAs titer ≥1:320, whereas as few as 14 (8.4%) controls had positive ANAs (p < 0.007). 
ANA-positive patients were more commonly diagnosed with unprovoked (n = 55; 57.4%) than provoked 
VTE (n = 39; 40.6%) (p = 0.03). A similar observation was made for ANAs titer ≥1: 320 (26 patients with 
unprovoked vs 20 patients with provoked VTE, p = 0.04). The presence of ANAs in the patient group did 
not correlate with age, sex, time since the VTE event, type of anticoagulation and its quality, inflammatory 
markers and D-dimer.
Conclusions. The prevalence of positive ANAs was 5 times higher among VTE patients than in controls. 
Antinuclear antibodies occur commonly in VTE and might be involved in the pathogenesis of unprovoked VTE.
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Introduction
Venous thromboembolism (VTE), encompassing deep 
vein thrombosis (DVT) and pulmonary embolism (PE), 
is  a  multifactorial disease.1 Venous thromboembolism 
is considered to be “provoked” in the presence of a tempo-
rary or reversible risk factor (such as surgery, trauma, im-
mobilization, pregnancy, oral contraceptive use or hormone 
replacement therapy) within the last 6 weeks to 3 months 
before diagnosis, and “unprovoked” in the absence thereof. 
The identification of potential risk factors plays a crucial role 
in the decision-making process about the duration of ther-
apy. Patients with antiphospholipid syndrome, those with 
a deficiency of antithrombin, protein C or protein S, and 
patients homozygous for factor V Leiden or prothrombin 
G20210A (PTG20210A), may be candidates for indefinite an-
ticoagulant treatment after a 1st unprovoked VTE.2 Modern 
thrombophilia testing fails to identify any underlying pro-
thrombotic tendency in a significant number of patients pre-
senting with objectively confirmed VTE.3 Overall, 25–50% 
of patients with the first-time VTE have an idiopathic condi-
tion, without a readily identifiable risk factor.4
Correlative studies have hinted at a relationship between 
DVT and immune responses mainly associated with DNA 
and neutrophils leading to a concept of immunothrombo-
sis.5 Growing evidence suggests that activation of blood 
coagulation exerts critical protective functions during in-
flammation. However, it has been hypothesized that dys-
regulated immunothrombosis may lead to VTE.
Antinuclear antibodies are considered to  promote 
the thrombotic tendency directly by causing intimal dam-
age due to their binding to the intimal cell wall and indi-
rectly by causing a disorder of the intimal function due 
to their binding to intracellular structures of intimal cells 
such as the nucleus and cytoplasm.6,7 Unlike antiphospho-
lipid antibodies, which bind to the cell wall in a restricted 
manner, ANAs bind to various cell components and may 
contribute to the thrombotic tendency by diverse mecha-
nisms. Moreover, ANAs are involved in vascular disorders 
such as Raynaud’s phenomenon.7
To the best of our knowledge, there have been no reports 
on the association between ANAs and VTE. Thus, the aim 
of our study was to investigate the prevalence of ANAs 
in patients following VTE. 
Material and methods
Patients
We recruited 283 consecutive patients following docu-
mented provoked or unprovoked VTE (aged 18–66 years) 
who were referred to the Center for Coagulation Disorders 
in the John Paul II Hospital (Kraków, Poland) for further 
laboratory work-up between June 2013 and September 
2015. Minimum time from the acute VTE episode prior 
to recruitment was 3 months. All the patients were treated 
with low molecular weight heparins followed by oral an-
ticoagulants. The exclusion criteria were: acute coronary 
syndrome or stroke within the preceding 6 months, known 
malignancy, signs of acute infection or acute VTE, long-
term antithrombotic treatment for other indications, e.g., 
atrial fibrillation or prosthetic cardiac valve implantation, 
pregnancy or postpartum period, end-stage kidney disease, 
documented autoimmune diseases (n = 56, 19.79%), includ-
ing antiphospholipid syndrome (APS) diagnosed in 48 pa-
tients (16.9%). Patients receiving anticoagulant therapy 
were eligible. The final analysis included 227 VTE patients. 
The Bioethics Committee of the Jagiellonian University 
approved the study. All the participants signed written in-
formed consent.
The  data on  demographic characteristics, risk factors 
for  VTE, comorbidities and medications was collected. 
The diagnosis of DVT of the lower or upper limb required 
a positive finding of color duplex sonography; an iliac/caval 
DVT was defined as abnormal duplex flow patterns typical 
of thrombosis or an intraluminal filling defect on contrast 
computed tomography or magnetic resonance venography. 
The diagnosis of PE was based on the presence of typical 
symptoms and positive results of high-resolution spiral com-
puted tomography. Individuals with thrombosis at unusual 
sites were also diagnosed. Cerebral sinus venous thrombosis 
and hepatic/portal/splanchnic vein thrombosis was objec-
tively documented using computed tomography angiography, 
magnetic resonance or magnetic resonance angiography.
Provoked VTE, i.e., associated with a known transient risk 
factor, was diagnosed in patients with VTE who experienced 
immobilization, surgery with the use of general anesthetic, 
major trauma, leg fracture or lower extremity plaster cast 
or hospitalization in the past month, intake of estrogen-con-
taining oral contraceptives or hormone replacement therapy 
(HRT), as well as pregnancy or delivery within 3 months pre-
ceding the index event. Unprovoked (idiopathic) VTE episode 
was defined in patients who had no history of cancer, sur-
gery, major trauma, plaster cast or hospitalization in the past 
month, pregnancy or delivery in the past 3 months.
A  control population consisted of  concurrent age-
matched healthy 165 participants.
Laboratory tests
After an overnight fast, venous blood was drawn from 
the antecubital vein into citrated tubes (9:1 of 0.106 M 
sodium citrate) and was centrifuged at  2500  g at  20°C 
for 10 min and stored in aliquots at −80°C until analysis. 
Blood drawn into serum tubes was centrifuged at 2500 g 
at −20°C for 10 min and stored at −80°C. To determine 
blood cell count, lipid profile, glucose, creatinine and thy-
roid-stimulating hormone (TSH), routine laboratory as-
says were used. High-sensitivity C-reactive protein (CRP) 
was determined using immunoturbidimetry (Roche Diag-
nostics, Mannheim, Germany). Fibrinogen was measured 
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by the von Clauss method (Instrumentation Laboratory, 
Bedford, USA). Plasma D-dimer was measured with the In-
novance D-dimer assay (Siemens, Marburg, Germany).
Antibodies directed at various cellular compartments 
including nuclear constituents, components of the nucle-
ar envelope, mitotic spindle apparatus, cytosol, cytoplas-
mic organelles and cell membranes (ANAs) were tested 
by immunofluorescence (IIF) in IgG isotype (HEp2 cells 
and the conjugate; Euroimmun, Lübeck, Germany). Pa-
tients’ sera were diluted with the cut-off 1:100 in PBS with 
Tween  20 (Sigma-Aldrich, St. Louis, USA), according 
to the international recommendations for the assessment 
of autoantibodies to cellular antigens.8 Visual determina-
tion of the staining pattern was assessed using the Nikon 
Eclipse E400 fluorescence microscope (Nikon Instruments 
Europe B.V., Amsterdam, Netherlands). The specific immu-
nofluorescence patterns observed at serum dilution equal 
to or greater than 1:100 were considered as positive ANAs. 
An additional analysis for subjects with ANAs titer ≥1:320 
was performed to confirm and strengthen the observations 
made for the whole ANA-positive patients’ group.
The anti-DFS70 pattern was characterized by dense fine 
speckles distributed in the nucleus, confirmed in a refer-
ence laboratory of Euroimmun in Lübeck and subjected 
to semiquantitative enzyme-linked immunosorbent assay 
(ELISA) analysis (Euroimmun, Lübeck, Germany), accord-
ing the manufacturer’s instructions.
All patients were screened for thrombophilia, includ-
ing the factor V Leiden mutation, prothrombin G20210A, 
as well as deficiency of antithrombin, protein C or pro-
tein S. Inherited thrombophilia was defined as the pres-
ence of either of the 2 mutations or a deficiency of 1 of the 3 
coagulation inhibitors. Genotypes of FV Leiden (rs6025) 
and prothrombin G20210A (rs1799963) polymorphisms 
were ascertained by the allelic discrimination test using 
the TaqMan Genotyping assay on the ABI PRISM 7900HT 
Fast Real-Time PCR System (Life Technologies Co., Carls-
bad, USA). Antithrombin anti-FX activity was measured 
using a chromogenic method in the presence of heparin 
(HemosIL™ TH, Instrumentation Laboratory SpA, Milan, 
Italy). Plasma PC was quantified using the HemosIL™ Pro-
tein C chromogenic assay (Instrumentation Laboratory 
SpA, Milan, Italy). Free PS was quantified using the He-
mosIL™ Free Protein S latex ligand immunoassay (Instru-
mentation Laboratory SpA, Milan, Italy).
To exclude APS based on the modified APS classification 
criteria by Miyakis et al., lupus anticoagulant (LA) was 
estimated using a clot-based assay, according to the recom-
mendations published in 2009.9,10 Anticardiolipin and anti-
β2GP-I antibodies were determined by immunoenzymatic 
assays (INOVA Diagnostics, San Diego, USA). Reference 
ranges for IgG were up to 15 IgG phospholipid unit (GPL) 
and 8 standard IgG β-2 glycoprotein unit (SGU), respective-
ly, and for IgM up to 17 IgM phospholipid unit (MPL) and 
10 standard IgM β-2 glycoprotein unit (SMU), respectively. 
All positive cases were reevaluated after 12–16 weeks.11
Serum protein profile was evaluated using serum protein 
electrophoresis (SPE) with the fully automated instrument 
Interlab G26 (Interlab, Rome, Italy) on agarose gel plates 
at pH 8.9. The final protein concentration ranged from 
60 g/L to 80 g/L. Densitometry of the pattern was deter-
mined for the relative quantification of protein zones.
Statistical analysis
Continuous variables were presented as  median and 
interquartile range. Categorical variables were presented 
as the number and percentages. The Shapiro-Wilk test was 
used to test the normality of continuous variables. To ex-
amine the differences between the independent groups, 
the Kruskal-Wallis test was used. The χ2 or Pearson’s exact 
tests were used for categorical variables. Statistical anal-
ysis was performed with STATISTICA v. 12.0 (StatSoft, 
Tulsa, USA).
Results
The demographic and laboratory data of  the control 
and VTE patients are summarized in Table 1. Of the 165 
control subjects, as few as 14 (8.4%) individuals had posi-
tive ANAs, of whom 8 (4.8%) had ANAs titer = 1:100 and 
6 (3.6%) had ANAs titer = 1:320.
Of the 227 VTE patients studied, 94 (42.2%) individuals 
had positive ANAs, including 62 patients (64.6%) with ANAs 
titer <1:320 and 32 patients (33.3%) with ANAs titer ≥1:320.
The prevalence of positive ANAs was 5 times higher 
among VTE patients compared with the controls (42.2% vs 
8.4%, p = 0.007). Of importance, patients with unprovoked 
VTE had positive ANAs more commonly (n = 55; 57.4%) 
than those with provoked VTE (n = 39; 40.6%) (p = 0.03). 
A similar observation was made regarding the ANAs titer 
≥1:320 (26 (27.1%) patients with unprovoked vs 20 (20.8%) 
patients with provoked VTE, p = 0.04).
The presence of ANAs was correlated with albumin 
(r = 0.4, p = 0.014) and gamma globulin levels (r = 0.5, 
p = 0.019). The positive ANAs did not correlate with any 
other examined demographic or clinical variables like age, 
gender, body mass index (BMI), smoking, C-reactive protein 
(CRP), glucose, fibrinogen, D-dimer, time since last VTE 
event, as well as type of anticoagulation and its quality.
Anti-DFS70 antibodies were screened in 149 (90.3%) 
control patients and 222 (97.8%) VTE patients. There was 
no difference in the prevalence of anti-DFS70 antibodies 
in the control and VTE patients (n = 6 (4.03%) vs n = 9 
(4.05%), respectively, p = 0.8). The DFS70 positive patients 
from the 2 groups did not differ in any of the examined 
demographic or clinical variables (data not shown).
The ANA-negative patients did not differ from ANA- 
-positive patients in any of examined parameters such 
as lipid profile, glucose, CRP, fibrinogen, D-dimer, TSH 
or time since the VTE event.
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Discussion
To  our knowledge, this study is  the  first to  show 
that  the  presence of  ANA among patients with VTE 
is higher than in control subjects. Based on  this find-
ing we hypothesize that ANA may play a potential role 
in the pathogenesis of VTE and might have a predictive 
value when it persists. Our rationale is that the individu-
als with autoimmune diseases are at a higher risk of VTE. 
However, this risk was mainly attributed to APS and/or ex-
acerbation of autoimmune diseases, with the maximum 
rates within the first years since diagnosis, in particular 
in systemic lupus erythematosus (SLE) and anti-neutrophil 
cytoplasmic antibodies.12,13 Surprisingly, little is known 
about ANA in VTE patients without diagnosed autoim-
mune disease.
The link of APS to VTE is well established.14 Antiphos-
pholipid syndrome is a complex autoimmune thrombotic 
disorder with defined clinical phenotypes, and experimental 
evidence suggests that antiphospholipid antibodies (aPLAs) 
play a causative role in vascular thrombosis and obstet-
ric complications; however, the mechanisms are not well 
understood.15
Numerous mechanisms of thrombosis in the APS have 
been proposed.16 At least some of the variety of mecha-
nisms may be explained by the spectrum of autoantibody. 
Mechanisms of autoantibody-mediated thrombosis may 
be divided into 2 general types: (1) autoantibodies inter-
fere with hemostatic components occurring on membrane 
surfaces, for example the ability of certain autoantibodies 
to prolong in-vitro coagulation assays, and (2) autoantibody 
engagement of antigens on cell surfaces leads to transduc-
tion of a signal and altered cell activity.17,18
Moreover, several studies have reported that autoanti-
bodies are associated with increased procoagulant activity 
on circulating blood monocytes. Tissue factor (TF), a ma-
jor initiator of normal and pathological blood coagulation, 
can be expressed in larger amounts on monocytes and 
endothelial cells by a variety of stimuli, including circulat-
ing antibodies.19 Moreover, monocyte-derived TF has been 
shown to be a key player in the initiation and propagation 
of VTE.5 It might be speculated that the presence of ANA 
may enhance TF expression and contribute to a low grade 
prothrombotic state, which increases the risk of throm-
bosis and/or  its recurrence especially when additional 
thrombotic risk factors occur, e.g. immobilization, obe-
sity or HRT.
A separate issue that needs to be addressed is the poten-
tial involvement of autoantibodies in immunothrombo-
sis. It has been demonstrated that autoantibodies against 
beta2-glycoprotein I (β2GPI) promote thrombin generation 
in vitro.19 This potentially sets up a vicious prothrom-
botic cycle and predisposes to VTE. It is, therefore, likely 
that other autoantibodies in a similar manner might lead 
to the activation of thrombotic mechanisms by endothelial 
cell damage and dysfunction. Since it is known that as few 
as 2–5% patients with elevated aPLAs levels do not develop 
thromboembolic events, it is possible that positive ANAs 
could also have some predictive value.20
ANA detected in our group of patients were unspecific; 
we did not find any disease-specific antibodies. The sub-
set of autoantibodies most commonly found in “appar-
ently healthy” individuals and several inflammatory non-
rheumatic diseases are anti-DFS70 antibodies, directed 
against epithelium-derived growth factor p75, which are 
usually absent in defined autoimmune diseases.21 Recently, 
positive anti-DFS70 antibodies have been shown to be as-
sociated with idiopathic VTE, arterial thrombosis and/or 
obstetric complications.22 In our study, however, we did 
not observe any association of anti-DFS70 antibodies and 
VTE, which might be explained by the analysis of patients 
below 65 years of age free of known autoimmune disorders. 
A potential role of anti-DFS70 antibodies in VTE requires 
further investigation.
Furthermore, it remains to be elucidated whether ANAs 
in VTE are primary or rather result from the disease itself, 
which is important for elucidating their role in thrombosis. 
Therefore, it might be useful to monitor the persistence 
of ANAs over a longer period of time.
It also is important to note that it is likely that by defin-
ing the potential relationship between ANAs and VTE, 
we might develop new diagnostic tools to identify patients 
at risk of VTE, especially unprovoked episodes.
In conclusion, our study indicates that positive ANAs, 
though at low titers, are common in young and middle-
aged patients following VTE, regardless of the time since 
the event, its type and anticoagulant therapy. More com-
monly, ANAs can be detected among patients after un-
provoked VTE, which might suggest that autoimmune 
reactions could be involved in the pathogenesis of VTE. 
It would be also of  interest to assess the role of ANAs 
as a potential risk factor of the VTE recurrence during 
a long-term follow-up in a large cohort study. Moreover, 
the predictive role of VTE in the development of symptom-
atic autoimmune disease in the future requires a further 
follow-up study.
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